Author

Peled N

Head, Shaare Zedek Cancer Center, Jerusalem, Israel - Cited by 32,271 - Precision Oncology - Lung Cancer - Thoracic Malignancies - Translation Research

Biography

Peled NThoracic Cancer Research and Detection Center, Sheba Medical Center, Tel Aviv University, Medical Oncology , Pulmonary Medicine Fellowship Research Interest:- Sublingual flumazenil; Hepatic encephalopathy; Insomnia  
Title
Cited by
Year
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ...Journal of Thoracic Oncology 16 (10), 1647-1662, 2021202
216
2021
Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza, E Felip, E Esteban, M Dómine, ...Journal of Clinical Oncology 41 (11), 1992, 232
20
2023
UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in First-LiNe setting (UNICORN)
J Bar, N Peled, S Schokrpur, M Wolner, O Rotem, N Girard, FA Nana, ...Journal of thoracic oncology 18 (2), 169-180, 202320202
20
2023
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro)+ pemetrexed (pem) and platinum vs placebo (pbo)+ pem and platinum for metastatic nonsquamous NSCLC
MC Garassino, SM Gadgeel, G Speranza, E Felip, EE Gonzalez, ...Annals of Oncology 33, S992-S993, 222
20
2022
Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study
W Kian, M Zemel, EH Kestenbaum, K Rouvinov, W Alguayn, D Levitas, ...Medicine 101 (2), 2022202
11
2022
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
N Peled, W Kian, E Inbar, IM Goldstein, M Zemel, O Rotem, ...Neuro-oncology advances 4 (1), vdab188, 2022202
9
2022
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
JW Riess, S Rahman, W Kian, C Edgerly, AM Heilmann, R Madison, ...Translational Oncology 14 (10), 101184, 2021202
7
2021
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
O Illini, H Fabikan, A Swalduz, A Vikström, D Krenbek, M Schumacher, ...Therapeutic advances in medical oncology 14, 1588359221103206, 2022202
7
2022
P47. 11 COMPEL: chemotherapy with/without osimertinib in patients with EGFRm advanced NSCLC and progression on first-line osimertinib
LV Sequist, N Peled, A Tufman, L Servidio, J Li, R Taylor, J ZhaoJournal of Thoracic Oncology 1 (10), S1101, 2021202
6
2021
Next-generation sequencing liquid biopsy-guided osimertinib rechallenge in EGFR-mutated advanced non-small-cell lung cancer patients
V Fuchs, W Kian, R Lichtenberg, JM Cooper, AA Remilah, D Levin, ...Clinical Drug Investigation 42 (2), 185-192, 2022202
6
2022
Lung cancer screening: a critical appraisal
W Kian, M Zemel, D Levitas, W Alguayn, AA Remilah, NA Rahman, ...Current Opinion in Oncology 34 (1), 3-43, 2022202
6
2022
Crizotinib in MET exon 14-mutated or MET-amplified in advanced disease non-small cell lung cancer: A retrospective, single institution experience
W Shalata, A Yakobson, S Weissmann, E Oscar, M Iraqi, W Kian, N Peled, ...Oncology 100 (9), 467-474, 2022202
5
2022
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
A Addeo, M Hochmair, U Janzic, E Dudnik, A Charpidou, A Płużański, ...Therapeutic advances in medical oncology 13, 17883921109874, 2021202
5
2021
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
W Kian, P Christopoulos, AA Remilah, E Levison, E Dudnik, W Shalata, ...Frontiers in Oncology 12, 1010311, 2022202
4
2022
Liquid first is “solid” in naïve non-small cell lung cancer patients: Faster turnaround time with high concordance to solid next-generation sequencing
O Sehayek, W Kian, A Onn, R Stoff, HG Sorotsky, M Zemel, J Bar, ...Frontiers in Oncology 12, 912801, 2022202
3
2022
Prophylactic topical treatment for EGFR inhibitor-induced papulopustular rash: a randomized clinical trial
I Amitay-Laish, H Prag-Naveh, A Ollech, B Davidovici, YA Leshem, I Snast, ...Dermatology 27 (6), 988-994, 2021202
3
2021
ALK inhibitors or chemotherapy for third line in ALK-positive NSCLC? Real-world data
M Moskovitz, E Dudnik, S Shamai, Y Rotenberg, N Popovich-Hadari, ...The Oncologist 27 (1), e76-e84, 2022202
3
2022
Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report
B Nisman, K Oleinikov, H Nechushtan, O Maimon, K Atlan, N Peled, ...Journal of Thoracic Oncology 18 (3), 369-376, 030
2
2023
P47. 10 Neoadjuvant osimertinib in EGFR-mutant stage IIIA/B NSCLC-A phase 2 open-label pilot study
P47. 10 Neoadjuvant osimertinib in EGFR-mutant stage IIIA/B NSCLC-A phase open-label pilot studyW Kian, LC Roisman, E Chernomordikov, AM Allen, B Corn, E Dudnik, ...Journal of Thoracic Oncology 16 (10), S1100, 010
2
2021
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a …
A Raphael, E Dudnik, D Hershkovitz, S Jain, S Olsen, L Soussan-Gutman, ...Journal of Clinical Medicine 11 (9), 475, 0
2
2022

Referred From: https://scholar.google.com/citations?user=_tIQj2cAAAAJ&hl=en&oi=sra

Cited by
Citations 32271
h-index 71
i10-index 172
Recommended Journals
Open Access Journals